HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of low-dose warfarin on antithrombin III levels in morbidly obese patients.

Abstract
Morbid obesity has been associated with increased risks for thrombotic diseases. Patients with morbid obesity are shown to have decreased activity and decreased concentration of antithrombin (AT) III. This deficit can be corrected by giving the patients low doses of the oral anticoagulant warfarin. The same beneficial effect was not observed in normal lean control volunteers in whom the levels of AT III were normal at all times. Thus, it may be possible to offer prophylactic protection against the effects of having depressed levels of AT III in patients at increased risk for thrombotic diseases without using full anticoagulant doses of warfarin, including morbidly obese patients.
AuthorsM M Bern, A Bothe Jr, B Bistrian, G Batist, E Haywood, G Blackburn
JournalSurgery (Surgery) Vol. 94 Issue 1 Pg. 78-83 (Jul 1983) ISSN: 0039-6060 [Print] United States
PMID6857515 (Publication Type: Journal Article)
Chemical References
  • Warfarin
  • Antithrombin III
Topics
  • Antithrombin III (analysis)
  • Humans
  • Obesity (complications)
  • Thrombosis (etiology, prevention & control)
  • Warfarin (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: